KDR and metabolic dysfunction-associated steatohepatitis: Coulon and colleagues used specific antibodies to block vascular endothelial growth factor receptor 2 (VEGFR2) and found that liver inflammation and liver vasculature were significantly improved in the MCD-induced mouse NASH model, both in a preventive and therapeutic setting (Coulon et al., 2013).